Profound Medical Corp sees a notable uptick in stock price, reflecting investor optimism.
Profound Medical Corp (PRN.TO) experienced a robust gain of 3.39% in the last trading session, closing at CA$9.75. This positive movement comes amidst a backdrop of significant operational achievements and financial growth, positioning the company favorably in the eyes of investors.
Investor takeaway: With strong revenue growth reported in Q1 2026 and strategic financial maneuvers, Profound Medical is capturing investor interest, suggesting a bullish outlook for the near term.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Profound Medical Corp
PRN.TO
PRN.TO
Profound Medical Corp
WealthAwesomeMarket cap
$348.84M
52W high
$12.40
52W low
$5.23
1W change
-5.51%
Beta
0.53
Analyst Price Targets
Based on analyst covering PRN
Wall Street analysts forecast PRN stock price to rise 160.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.03
+160.7% Upside
Current Price
C$9.60
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PRN's historical volatility
30-Day Vol
40.5%
Annualized
90-Day Vol
57.4%
Annualized
Trend (90d)
+11.5%
Annualized drift
90d Mean
C$10.00
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.73 | C$8.46 – C$11.19 |
| 60 trading days | C$9.87 | C$8.10 – C$12.03 |
| 90 trading days | C$10.00 | C$7.85 – C$12.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Bull case
Profound Medical's recent revenue growth of 104% in Q1 2026 and the addition of Humana coverage for the TULSA Procedure™ indicate strong operational performance and market acceptance. These developments could lead to further stock appreciation.
Bear case
Despite the positive momentum, investors should remain cautious. The company still operates at a loss, with a profit margin of -2.07%, which could affect its long-term sustainability.
Strong Financial Performance
Profound Medical recently reported a staggering 104% increase in revenue for Q1 2026, showcasing its ability to grow despite market challenges. This financial success is a key driver behind the stock's upward movement, as investors respond positively to the company's operational efficiency and market strategies.
Strategic Developments Enhance Market Position
The addition of Humana coverage for the TULSA Procedure™ is a significant milestone for Profound Medical, enhancing its market presence and accessibility. This strategic move not only expands the company's reach but also reinforces investor confidence in its growth trajectory.
Advertisement
